About Hanmi

�ѹ̾�ǰ�� â���� ������ ��ġ�� �žళ�߿� �����ϴ� R&D�߽� �������Դϴ�.



  • Aug. 1st rank for outpatient prescriptions in the first half for 4 consecutive years
  • Jul. Hanmi-Lego ChemBio jointly develop dual antibody ADC anticancer drug
  • NIH visits Hanmi Fine Chemicals on-site verification of mRNA competency
  • Jun. Founder of Hanmi, 'Lim Seong-ki Foundation' launched
  • Joint research on innovative new drug targeting lung cancer with Dankook University
  • May. President Woo, received the Gold Tower medal of Industrial Merit on the Day of Invention
  • Hanmi-Genexin, Covid 19 Vaccine Production Contract
  • US FDA additionally designates LAPSTriple Agonist as an orphan drug
  • Apr. AmosartanQ enters Russian Market
  • US FDA designates LAPSGLP-2 Analog as a Fast Track
  • Hanmi received a commendation from the Fair Trade Commissioner
  • Mar. Opened Daycare Center for children of employees
  • New biologic drug Rolontis, first approval in Korea
  • US FDA designates Poziotinib as a Fast Track
  • Rosuzet enters Mexico Market
  • Feb. NASH Innovative Drug, awarded Korea New Drug Development Technology
  • Rosuzet achieved No. 1 in sales of prescription drugs in korea
  • Launched the world's first 4 drug complex 'Amosartan XQ'
  • Jan. 1st rank for outpatient prescriptions for 3 consecutive years
  • FDA approves Phase 2 clinical trial for two innovative drugs of Hanmi
  • Launched the world's first Esomeprazole double delayed release 'Esomezoldial'